Tofogliflozin and Pemafibrate Combination Therapy Prevents Nonalcoholic Steatohepatitis (NASH) Development of Novel Metabolic Syndrome-Related NASH Model Mice

被引：0
|
作者：
Sasaki, Yusuke
Asahiyama, Masato
Kamiya, Wakana
Sakai, Juro
Kodama, Tatsuhiko
Tanaka, Toshiya
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-1153-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Therapeutic effects of bezafibrate to high-fat and high-cholesterol (HFHC) diet-induced nonalcoholic steatohepatitis (NASH) model in mice
    Moritani, Toshinori
    Shimosato, Takashi
    Abe, Yuki
    Makino, Ayumi
    Kimura, Kagari
    Minobe, Noriko
    Okajima, Takumi
    Kosugi, Shoko
    Matsuda, Hitomi
    Ishimoto, Akihiro
    Iidaka, Takeshi
    Kimura, Ayahito
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2017, 133 (03) : S257 - S257
  • [42] Further study of development of an experimental non-alcoholic steatohepatitis (NASH) model in mice (2nd report)
    Ushijima, Souta
    Morizumi, Kousuke
    Atai, Hiroshi
    Nishi, Katsuhide
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 149P - 149P
  • [43] FXR Activation Abrogates Steatohepatitis, Inflammation, Fibrosis, Metabolic Syndrome, and Leaky Gut in Newly Developed Dietary Mouse Model of Nash
    Ksiazek, Iwona
    Bringer, Pauline
    Gapp, Berangere
    Jourdain, Marie
    Kueng, Benjamin
    Weber, Delphine
    Zurbruegg, Stefan
    Beckmann, Nicolau
    Nigsch, Florian
    Molteni, Valentina
    Valdez, Reginald
    Dietrich, Bill
    Badman, Michael
    [J]. HEPATOLOGY, 2018, 68 : 440A - 440A
  • [44] Combination therapy of lanifibranor and firsocostat further improves steatohepatitis and fibrosis compared to monotherapy in a diet-induced murine model of NASH
    Wettstein, Guillaume
    Briand, Francois
    Sulpice, Thierry
    Junien, Jean-Louis
    Broqua, Pierre
    [J]. JOURNAL OF HEPATOLOGY, 2021, 75 : S595 - S596
  • [45] Metabolic Syndrome (MetS) and Nonalcoholic Steatohepatitis (NASH) Study of biochemical markers Free Fatty Acid (FFA), Total Antioxidant Status (TAOS), Adiponectin, Transforming Growth Factor (TGF-beta 1), in occurence of NASH
    Sulaeman, Agus
    Amiruddin, A. Rifai
    Lawrence, Gatot S.
    [J]. INDONESIAN BIOMEDICAL JOURNAL, 2009, 1 (01): : 40 - 44
  • [46] Intervention with Caspase-1 inhibitor attenuates the metabolic syndrome and prevents non alcoholic-steatohepatitis (NASH) in high fat diet-fed LDLR-/-.Leiden mice
    Wielinga, P. Y.
    van den Hoek, A. M.
    Salic, K.
    Liang, W.
    Kooistra, T.
    Kleemann, R.
    [J]. DIABETOLOGIA, 2014, 57 : S117 - S117
  • [47] Triple Combination Therapy of GLP-1 Receptor Agonist Semaglutide with an FXR Agonist and AC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice
    Norlin, Jenny
    Miranda, Diego A.
    Bates, Jamie G.
    Zois, Nora E.
    Veidal, Sanne
    Feigh, Michael
    Trevaskis, James L.
    Latta, Markus
    [J]. DIABETES, 2020, 69
  • [48] Vitamin E and L-Carnitine Prevents Progression of Non-Alcoholic Steatohepatitis With Regulation of Intestinal Inflammasome Activation in NASH Model Mice
    Ishikawa, Hisashi
    [J]. GASTROENTEROLOGY, 2013, 144 (05) : S1019 - S1019
  • [49] Novel Rho associated coiled kinase inhibitor improves hepatic fibrosis in mice model of non-alcoholic steatohepatitis (NASH)
    Ali, Quaisar
    Prakash, Natalia
    Dalapati, Sony
    Li, Jingsong
    Goldberg, Itzhak
    Paka, Latha
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S524 - S524
  • [50] Development of nonalcoholic steatohepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice
    Ito, M
    Suzuki, J
    Sasaki, M
    Watanabe, K
    Tsujioka, S
    Takahashi, Y
    Gomori, A
    Hirose, H
    Ishihara, A
    Iwaasa, H
    Kanatani, A
    [J]. HEPATOLOGY RESEARCH, 2006, 34 (02) : 92 - 98
12345